Global Cardiology PoC Diagnostics Market Revenue Grows at a CAGR of 5.68%

Introduction

Straits Research released its highly anticipated report, “Global Cardiology PoC Diagnostics Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 2.05 billion in 2025 and is anticipated to grow to USD 3.36 billion by 2034, growing at a CAGR of 5.68% from 2026-2034.

Market Dynamics

The global cardiology point-of-care (PoC) diagnostics market is driven by the growing burden of cardiovascular diseases, the ageing population, and increasing demand for rapid, accurate, and bedside diagnostic solutions. Advancements in high-sensitivity cardiac biomarker assays, including troponin and BNP, along with the integration of portable and connected PoC platforms, are enhancing clinical decision-making and enabling faster treatment initiation. However, the market faces restraints such as stringent regulatory approvals, variability in reimbursement structures, and limited accessibility in resource-constrained healthcare settings due to a shortage of trained personnel. Despite these challenges, emerging markets and the expansion of decentralized and home-based care models present lucrative opportunities, as innovations in AI-enabled PoC devices and cloud-integrated data management are transforming cardiac diagnostics toward more patient-centric and cost-effective care delivery.

Market Highlights

• Based on Product, the cholesterol/lipid profile test dominated the market in 2025 with a revenue share of 39.42%.
• Based on Technology, the lateral flow test (LFT) dominated the market with a revenue share of 47.25%.
• Based on End User, diagnostic laboratories dominated the market in 2025, with a revenue share of 42.34%.
• Regional Insights: North America dominated the market with more than 35.47% of market share in 2025.

Competitive Players

1. Abbott
2. Hoffmann-La Roche Ltd
3. Siemens Healthineers AG
4. Danaher Corporation
5. BD
6. bioMérieux SA
7. Bio-Rad Laboratories, Inc.
8. QuidelOrtho Corporation
9. Nova Biomedical, Inc.
10. Alfa Scientific Designs, Inc.
11. Ortho-Clinical Diagnostics
12. Trinity Biotech plc
13. Sekisui Diagnostics, LLC
14. Nipro Corporation
15. Hemocue AB
16. DiaSorin S.p.A.
17. Randox Laboratories Ltd.
18. Meso Scale Diagnostics, LLC
19. LifeSign LLC
20. Nano-Ditech Corporation
21. Others

Recent Developments

August 2025: Analytics for Life and CorVista Health announced positive results from a clinical study evaluating a non-invasive point-of-care (POC) diagnostic test for detecting elevated pulmonary capillary wedge pressure (PCWP), a key marker in heart failure management. The novel device, used machine learning to analyze patient signals in under four minutes, achieved its primary sensitivity endpoint for identifying PCWP levels associated with both HFpEF and HFrEF. This advancement represented a major step toward replacing invasive catheterisation procedures, strengthening the role of cardiac biomarkers and hospital-based POC diagnostics in advanced heart failure assessment.

Segmentation

1. By Product (2026-2034)
   1. Cholesterol/Lipid Profile Test
   2. Cardiac Bio/Markers
   3. Coagulation Test
   4. Companion Diagnostics
2. By Technology (2026-2034)
   1. Lateral Flow Test (LFT)
   2. Optical Liquid Analysis
   3. Electrical Biochemical Sensors
   4. Molecular Diagnostics
3. By End User (2026-2034)
   1. Hospitals
   2. Diagnostic Laboratories
   3. Home-based Testing
   4. Others